Showing 201 - 220 results of 1,702 for search '(regimen OR ((segments OR regimes) OR ((regimenss OR regress) OR regimens)))', query time: 0.18s Refine Results
  1. 201
  2. 202
  3. 203
  4. 204
  5. 205
  6. 206
  7. 207
  8. 208
  9. 209
  10. 210
  11. 211

    15.818 Pricing, Spring 2005 by Tucker, Catherine

    Published 2005
    Subjects:
    Get full text
    Learning Object
  12. 212

    The effect of early age feed restriction on subsequent response to high environmental temperatures in female broiler chickens by Zulkifli, I., Che Norma, M.T., Israf, D.A., Omar, A.R.

    Published 2000
    “…On Day 0, chicks were assigned to one of four feeding regimens; each regimen was applied to four cages of chicks. …”
    Get full text
    Article
  13. 213

    Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trial by Silk, SE, Kalinga, WF, Salkeld, J, Mtaka, IM, Ahmed, S, Milando, F, Diouf, A, Bundi, CK, Balige, N, Hassan, O, Mkindi, CG, Rwezaula, S, Athumani, T, Mswata, S, Lilolime, NS, Simon, B, Msami, H, Mohamed, M, David, DM, Mohammed, L, Nyaulingo, G, Mwalimu, B, Juma, O, Mwamlima, TG, Sasamalo, IA, Mkumbange, RP, Kamage, JJ, Barrett, JR, King, LDW, Hou, MM, Pulido, D, Carnrot, C, Lawrie, AM, Cowan, RE, Nugent, FL, Roberts, R, Cho, J-S, Long, CA, Nielsen, CM, Miura, K, Draper, SJ, Olotu, AI, Minassian, AM

    Published 2024
    “…Children received either 10 μg RH5.1 at 0, 1, and 2 months (Children 10M) or 10 μg RH5.1 at 0, 1, and 6 months (delayed third dose regimen; Children 10D), and were recruited in parallel, followed by children who received the dose-escalation regimen (Children DFx) and children with higher malaria pre-exposure who also received the dose-escalation regimen (High Children DFx). …”
    Journal article
  14. 214

    Analyses of human vaccine-specific circulating and bone marrow-resident B cell populations reveal benefit of delayed vaccine booster dosing with blood-stage malaria antigens by Barrett, JR, Silk, SE, Mkindi, CG, Kwiatkowska, KM, Hou, MM, Lias, AM, Kalinga, WF, Mtaka, IM, McHugh, K, Bardelli, M, Davies, H, King, LDW, Edwards, NJ, Chauhan, VS, Mukherjee, P, Rwezaula, S, Chitnis, CE, Olotu, AI, Minassian, AM, Draper, SJ, Nielsen, CM

    Published 2024
    “…Within protein/adjuvant groups, delayed boosting further improved B cell immunogenicity compared to a monthly boosting regimen. Consistent with this, delayed boosting also drove more durable anti-DBPRII serum IgG. …”
    Journal article
  15. 215

    Optimising statistical methodologies for estimating antimalarial efficacy for uncomplicated Plasmodium falciparum malaria by Dahal, P

    Published 2018
    “…For dihydroartemisinin-piperaquine (DP) regimen, a study with 42 day follow-up was estimated to miss 47% [95% CI: 19 – 90%] of the treatment failures in those who were adequately dosed. …”
    Thesis
  16. 216

    Novel viral vector vaccines for tropical infections by Rampling, T

    Published 2017
    “…Two studies evaluate the safety, efficacy and immunogenicity of a combination vaccination regimen containing the leading pre- erythrocytic <em>P. falciparum</em> malaria vaccine RTS,S/AS01B and the liver stage, viral vector heterologous prime-boost regimen of ChAd63 ME-TRAP and MVA ME-TRAP. …”
    Thesis
  17. 217

    Quality of life and compliance with fluid restriction among hemodialysis patients in Hospital Universiti Sains Malaysia by Mohamad, Siti Aniza

    Published 2023
    “…In conclusion, patients’ knowledge and practice of treatment regimens has to be enhanced and improved so they will be knowledgeable and able to comply to treatment regimens thus increasing their quality of life.…”
    Get full text
    Monograph
  18. 218

    Efficacy of cannabinoids for the prophylaxis of chemotherapy-induced nausea and vomiting—a systematic review and meta-analysis by Chow, R, Basu, A, Kaur, J, Hui, D, Im, J, Prsic, E, Boldt, G, Lock, M, Eng, L, Ng, TL, Zimmermann, C, Scotte, F

    Published 2025
    “…However, there was no difference between cannabinoid and active treatment alternatives (most using dated single-agent regimens) for any outcomes. A recent phase II/III trial demonstrated superior efficacy of THC:CBD for secondary prevention of CINV when used as adjunctive therapy alongside modern antiemetic regimens, albeit mostly without olanzapine. …”
    Journal article
  19. 219

    Investigating the impact of growth arrest mechanisms on tumour growth and responses to radiotherapy and hyperthermia by Colson, C

    Published 2023
    “…In each regime, we determine the biological processes that may underpin positive and negative treatment outcomes and assess which treatment (RT, HT or RT + HT) and dosing regimen maximise the reduction in tumour burden. …”
    Thesis
  20. 220